Nanoviricides (NNVC) EBT (2010 - 2026)

Nanoviricides has disclosed EBT across 17 years of filings, most recently posting -$2.0 million for Q1 2026.

• In Q1 2026, EBT rose 9.73% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$8.2 million (up 17.15% YoY), while the FY2025 annual figure was -$9.6 million, down 11.98% from the prior year.
• EBT came in at -$2.0 million for Q1 2026 at Nanoviricides, up from -$2.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$1.6 million in Q3 2022 to a low of -$3.7 million in Q2 2023.
• Average EBT over 5 years is -$2.1 million, with a median of -$2.0 million recorded in 2026.
• Year-over-year, EBT slumped 106.54% in 2023 and surged 43.28% in 2025.
• Over 5 years, EBT stood at -$1.7 million in 2022, then decreased by 25.95% to -$2.2 million in 2023, then increased by 6.32% to -$2.1 million in 2024, then decreased by 8.45% to -$2.2 million in 2025, then rose by 9.09% to -$2.0 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$2.0 million in Q1 2026, -$2.2 million in Q4 2025, and -$1.8 million in Q3 2025.